Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

Published on September 15, 2022 at 9:39 am by Omer Farooq in Hedge Funds, News

In this article, we will look at Harvard University’s latest stock portfolio and list its 10 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also take a look at Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks.

Harvard Management Company was founded in 1974 and has been a significant contributor to funding Harvard’s operations. Harvard Management Company manages Harvard University’s endowment which is among the largest academic endowments in the world, valued at $53.2 billion as of fiscal 2021.

Harvard Management Company seeks to generate risk-adjusted long-term returns on investment. The fund’s teams collaborate and determine the appropriate level of risk for its portfolio, which is in the best interests of Harvard. In fiscal 2021, Harvard Management Company delivered a return of 33.6%, and since 1974, Harvard Management Company has averaged a return of 11% on an annualized basis, up until 2021.

At the time of the 2008 mortgage crisis, Jane Mendillo was put in charge of managing Harvard Management Company’s endowment. Jane Mendillo joined Harvard Management Company as an equities analyst in 1987 and catered to various roles at the endowment including managing venture capital investments and managing the investment of charitable trusts up until 2001. In 2002, Jane Mendillo was recruited by Wellesley College as the chief investment officer of the university’s endowment. In 2008, Jane Mendillo returned to Harvard Management Company and was tasked with managing assets worth $36.9 billion. Jane Mendillo resigned from her role as CEO of Harvard Management Company in 2014, bringing its value to $36.4 billion.

In 2016, Narv Narvekar joined Harvard Management Company as the CEO. Mr. Narvekar has served as the CEO of Columbia University’s endowment and as the managing director for equity derivatives at JPMorgan Chase & Co. As of June 30, 2022, Mr. Narvekar manages $863.7 million in 13F securities.

In the second quarter of 2022, Harvard Management Company increased its stakes in 11 companies, reduced its stakes in one company, and initiated a position in one company. The fund has a top ten holdings concentration of 81.9% and has investments concentrated in the technology and healthcare segments. For the second quarter of 2022, Harvard Management Company returned 13.45% quarter-on-quarter. Some of the fund’s top technology holdings include Meta Platforms, Inc. (NASDAQ:META), Alphabet Inc. (NASDAQ:GOOG), and NVIDIA Corporation (NASDAQ:NVDA).

Our Methodology

To determine the 10 best biotech stocks to buy according to Harvard Management Company, we reviewed the fund’s second-quarter 2022 investment portfolio and looked for companies operating in the biotech industry. We narrowed down our selection to biotech stocks that make up the top of Harvard Management Company’s 13F portfolio and ranked them in increasing order of the fund’s stake in them. Along with each stock, we have included the hedge fund sentiment and analyst ratings.

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

10. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Harvard Management’s Stake Value: $3,791,000

Percentage of Harvard Management’s 13F Portfolio: 0.43%

Number of Hedge Fund Holders: 12

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a San Francisco-based biotechnology company that develops therapies for heart disease. As of June 30, Harvard Management Company owns roughly 0.67 million shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) which amounts to a stake of $3.7 million.

On July 6, Piper Sandler analyst Yasmeen Rahimi reiterated his $40 price target and a buy-side Overweight rating on Tenaya Therapeutics, Inc. (NASDAQ:TNYA).

On September 6, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced that it has received FDA clearance to begin clinical trials of TN-301, the company’s small molecule inhibitor for the treatment of heart failure with preserved ejection fraction.

At the close of Q2 2022, 12 hedge funds were long Tenaya Therapeutics, Inc. (NASDAQ:TNYA) and held stakes worth $58.3 million in the company. This is compared to 10 positions in the preceding quarter with stakes worth $122 million in the company.

In addition to healthcare, Harvard Management Company has hefty investments in the technology sector. Some of the fund’s most notable tech holdings include Meta Platforms, Inc. (NASDAQ:META), Alphabet Inc. (NASDAQ:GOOG), and NVIDIA Corporation (NASDAQ:NVDA).

9. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Harvard Management’s Stake Value: $3,988,000

Percentage of Harvard Management’s 13F Portfolio: 0.46%

Number of Hedge Fund Holders: 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company focused on the development and distribution of small molecule therapies for cancer and immune disorders. At the end of Q2 2022, 12 hedge funds were bullish on Nurix Therapeutics, Inc. (NASDAQ:NRIX) and held stakes worth $163.25 million in the company. This is compared to 20 hedge funds in Q1 2022, with stakes worth $129.7 million.

On July 7, Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced earnings for the second quarter of fiscal 2022. The company generated a revenue of $11.4 million, up 61.2% year over year, and outperformed Wall Street consensus by $0.93 million. As of September 14, Nurix Therapeutics, Inc. (NASDAQ:NRIX) has gained 20.6% over the past six months.

Shortly after the company’s earnings release, Stifel analyst Stephen Willey adjusted his price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $37 from $44 and maintained a Buy rating on the shares. On July 11, H.C. Wainwright analyst Robert Burns revised his price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $54 from $60 and reiterated a Buy rating on the shares.

As of June 30, Harvard Management Company owns 0.31 million shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) which amounts to a stake of $3.9 million. The investment covers 0.46% of the fund’s 13F portfolio.

8. Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Harvard Management’s Stake Value: $4,505,000

Percentage of Harvard Management’s 13F Portfolio: 0.52%

Number of Hedge Fund Holders: 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of fibrosis and related diseases in the United States. The company’s main product is the PLN-74809, an oral therapy for the treatment of idiopathic pulmonary fibrosis.

As of September 14, Pliant Therapeutics, Inc. (NASDAQ:PLRX) has gained 28.7% over the past twelve months.

On August 8, Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced earnings for the fiscal second quarter of 2022. The company generated a revenue of $4.9 million, up 178.8% year over year, and outperformed Wall Street consensus by $3.79 million.

Wall Street analysts are bullish on Pliant Therapeutics, Inc. (NASDAQ:PLRX). On August 9, H.C. Wainwright analyst Ed Arce raised his price target on Pliant Therapeutics, Inc. (NASDAQ:PLRX) to $53 from $45 and maintained a Buy rating on the shares. On September 1, Citi analyst David Lebowitz initiated coverage of Pliant Therapeutics, Inc. (NASDAQ:PLRX) with a Buy rating and a $36 price target.

At the close of Q2 2022, 17 hedge funds were bullish on Pliant Therapeutics, Inc. (NASDAQ:PLRX) and held stakes worth $63 million in the company. This is compared to 11 positions in the previous quarter with stakes worth $48.6 million. The hedge fund sentiment for the stock is positive.

As of June 30, Harvard Management Company’s stakes in Pliant Therapeutics, Inc. (NASDAQ:PLRX) are valued at $4.5 million. The investment covers 0.52% of Harvard Management Company’s 13F portfolio.

7. Kinnate Biopharma Inc. (NASDAQ:KNTE)

Harvard Management’s Stake Value: $6,280,000

Percentage of Harvard Management’s 13F Portfolio: 0.72%

Number of Hedge Fund Holders: 12

Kinnate Biopharma Inc. (NASDAQ:KNTE) is a biopharmaceutical company that engages in the discovery and development of small molecule kinase inhibitors for the treatment of genomically defined cancers in the United States. As of June 30, Harvard Management Company’s stakes in Kinnate Biopharma Inc. (NASDAQ:KNTE) are valued at $6.2 million, which covers 0.72% of the fund’s 13F portfolio.

On July 28, H.C. Wainwright analyst Robert Burns initiated coverage of Kinnate Biopharma Inc. (NASDAQ:KNTE) with a Buy rating and a $33 price target. The analyst noted that the company is “on the cutting edge of precision medicine in oncology.” As of September 14, Kinnate Biopharma Inc. (NASDAQ:KNTE) has surged 53.8% over the past six months.

At the end of the second quarter of 2022, 12 hedge funds held stakes in Kinnate Biopharma Inc. (NASDAQ:KNTE) and held stakes worth $169.84 million in the company. This is compared to 13 hedge funds in the preceding quarter with stakes worth $154.39 million.

Like Meta Platforms, Inc. (NASDAQ:META), Alphabet Inc. (NASDAQ:GOOG), and NVIDIA Corporation (NASDAQ:NVDA), Kinnate Biopharma Inc. (NASDAQ:KNTE) is among Harvard Management Company’s top 13F holdings.

6. 10x Genomics, Inc. (NASDAQ:TXG)

Harvard Management’s Stake Value: $8,423,000

Percentage of Harvard Management’s 13F Portfolio: 0.97%

Number of Hedge Fund Holders: 17

10x Genomics, Inc. (NASDAQ:TXG) is a biotechnology company that is involved in the development and commercialization of gene sequencing technology that is used in scientific research. On August 8, 10x Genomics, Inc. (NASDAQ:TXG) announced earnings for the fiscal second quarter of 2022. The company reported a revenue of $114.6 million.

On July 25, Canaccord analyst Kyle Mikson initiated coverage of 10x Genomics, Inc. (NASDAQ:TXG) with a Buy rating and a $55 price target. Mikson likes the company’s long-term growth story and sees a 57% upside to his price target. On August 9, Cowen analyst Dan Brennan raised the firm’s price target on 10x Genomics, Inc. (NASDAQ:TXG) to $55 from $50 and reiterated an Outperform rating on the shares.

At the close of the second quarter of 2022, 17 hedge funds held stakes in 10x Genomics, Inc. (NASDAQ:TXG) worth $512.6 million. This is compared to 22 positions in the previous quarter with stakes worth $541.3 million.

As of June 30, Harvard Management Company’s stake in 10x Genomics, Inc. (NASDAQ:TXG) is valued at $8.4 million. The investment covers 0.97% of the fund’s 13F portfolio.

Click to continue reading and see Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

Published on September 15, 2022 at 9:39 am by Omer Farooq in Hedge Funds, News

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

10. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

9. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

8. Pliant Therapeutics, Inc. (NASDAQ:PLRX)

7. Kinnate Biopharma Inc. (NASDAQ:KNTE)

6. 10x Genomics, Inc. (NASDAQ:TXG)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

Published on September 15, 2022 at 9:39 am by Omer Farooq in Hedge Funds, News

Share

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

10. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

9. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

8. Pliant Therapeutics, Inc. (NASDAQ:PLRX)

7. Kinnate Biopharma Inc. (NASDAQ:KNTE)

6. 10x Genomics, Inc. (NASDAQ:TXG)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff